AZD8848 clinical trials
Also written AZD8848.
- studies test it
- 9
- open now
- 0
- in phase 3
- 0
- first study started
- 2008
How each study uses AZD8848 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
9 studies that test it; most in 2010 (3)
| Year | Studies |
|---|---|
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 3 |
| 2012 | 1 |
| 2014 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Studies
Open first, then newest update. How each study uses AZD8848 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- DSP-3025 Study of Healthy Male Volunteers and Seasonal Allergic Rhinitis Male Patients Out of SeasonCompletedPhase 1Sumitomo Pharma Co., Ltd.NCT00925678Written as DSP-3025
- AZD8848 Single Ascending Dose StudyCompletedPhase 1AstraZenecaNCT01560234Written as AZD8848
- The Tolerability and Effects of AZD8848 in Allergic Asthma Subjects Challenged With Inhaled AllergenCompletedPhase 2AstraZenecaNCT00999466Written as AZD8848
- Efficacy Study in Allergic Rhinitis Patients After Intranasal Administration of AZD8848CompletedPhase 2AstraZenecaNCT01185080Written as AZD8848
- Study to Investigate the Safety and Tolerability of AZD8848 in Butyrylcholinesterase Deficient SubjectsCompletedPhase 1AstraZenecaNCT01205867Written as AZD8848
- A Study to Investigate the Impact of Dose and Dosing Frequency of AZD8848 on the Response on BiomarkersCompletedPhase 1AstraZenecaNCT01203124Written as AZD8848
- To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses AZD8848 in Healthy SubjectsCompletedPhase 1AstraZenecaNCT01818869Written as AZD8848
- Tolerability/Safety of Intranasal AZD8848 in Healthy Male Volunteers and Seasonal Allergic Rhinitis Male Patients Out of SeasonCompletedPhase 1AstraZenecaNCT00688779Written as AZD8848
- Tolerability/PoP Study in Allergic Rhinitis After Intranasal Administration of AZD8848CompletedPhase 1AstraZenecaNCT00770003Written as AZD8848
Codes
What other systems call AZD8848 · ClinicalTrials.gg INT000505
- Wikidata Q27074812AZD8848One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| Wikidata | Q27074812 | AZD8848 | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.